#6: Expedited Programs for Serious Conditions – Drugs and Biologics

December 8, 2016

In May 2014, the FDA published a guidance document entitled “Expedited Programs for Serious Conditions – Drugs and Biologics.”  The intention of the document was to provide drug makers with an incentive to develop products that fill unmet medical needs for serious conditions.  Since its publication, the program established by the guidance document has become an increasingly popular pathway for many companies developing new drug products.

To learn more about this guidance document and its contents, view our previous blog post on the topic, entitled “Taking the Mystery Out Of Expedited Approvals.”

Do you think your product may fall into the category of drugs covered by this incentive program?  Are you seeking expedited approval for an applicable drug product?  We can help you achieve a successful interaction with FDA.  To learn more about our services and capabilities, contact us today.

If you have any questions or thoughts on this blog post or others, please contact us today.

Agency Alerts General Regulatory

June 13, 2017

FDA Warns OTC Manufacturer After Finding Inaccurate Information in Product Listings

On Thursday, June 1st, the FDA issued a Warning Letter to Prestige Brands Holdings, an over-the-counter (OTC) drug manufacturer.  PediaCare Children’s Plus Multi-Symptom Cold and PediaCare Children’s...

Read the Full Article

April 18, 2022

FDA releases Guidance for Industry on Bioavailability Studies Submitted in NDAs or INDs — General Considerations

FDA issued a final guidance to drug sponsors on conducting and submitting bioavailability (BA) studies for drug products in investigational new drug applications (INDs), new drug applications (NDAs),...

Read the Full Article
Agency Alerts General Regulatory

November 27, 2018

FDA Takes Steps to Promote Digital Tools for Prescription Drugs

On Tuesday, November 20th, FDA announced the establishment of a public docket to solicit comments and feedback on a proposed framework regarding the regulation of prescription drug-use-related...

Read the Full Article